Advertisement
Canada markets close in 5 hours 24 minutes
  • S&P/TSX

    22,167.89
    +60.81 (+0.28%)
     
  • S&P 500

    5,252.28
    +3.79 (+0.07%)
     
  • DOW

    39,729.66
    -30.42 (-0.08%)
     
  • CAD/USD

    0.7376
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    82.38
    +1.03 (+1.27%)
     
  • Bitcoin CAD

    96,846.05
    +2,424.22 (+2.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,226.90
    +14.20 (+0.64%)
     
  • RUSSELL 2000

    2,120.08
    +5.73 (+0.27%)
     
  • 10-Yr Bond

    4.2040
    +0.0080 (+0.19%)
     
  • NASDAQ

    16,399.73
    +0.21 (+0.00%)
     
  • VOLATILITY

    13.05
    +0.27 (+2.11%)
     
  • FTSE

    7,959.16
    +27.18 (+0.34%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6823
    +0.0018 (+0.26%)
     

ReShape Lifesciences Announces 1-for-120 Reverse Stock Split

SAN CLEMENTE, CA / ACCESSWIRE / November 11, 2019 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-120 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 12, 2019. At that time, each 120 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. The number of authorized shares of common stock and preferred stock under the company's certificate of incorporation will not be reduced in connection with the reverse stock split.

The reverse stock split was approved by ReShape Lifesciences' stockholders at the company's special meeting of stockholders held on October 31, 2019. ReShape Lifesciences stockholders will receive instructions from the company's transfer agent, EQ Shareowner Services, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares. The new CUSIP number for the company's common stock following the reverse stock split will be 761123603.

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved Lap-Band® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

ADVERTISEMENT

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the Lap-Band system, our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and Lap-Band system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed May 16, 2019 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Brendan O'Connell
VP Finance and Corporate Controller
ReShape Lifesciences, Inc.
949-429-6680
ir@reshapelifesci.com

or

Debbie Kaster
Investor Relations
Gilmartin Group
415-937-5403
debbie@gilmartinir.com

SOURCE: ReShape Lifesciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/565867/ReShape-Lifesciences-Announces-1-for-120-Reverse-Stock-Split